United States Psilocybin Assisted Therapy Market Size & Outlook, 2025-2033
United States Psilocybin Assisted Therapy Market Insights
- Based on Reed Intelligence findings, the United States Psilocybin Assisted Therapy Market reached USD 593.85 Billion in 2024 and is estimated to attain USD 2241.42 Billion by 2033.
- From 2026 to 2033, the United States market is expected to grow at a steady CAGR of 15.8%.
- Within the By Application category, Depression dominated in 2024 in terms of market size contribution.
- Over the forecast period, Depression is forecasted to deliver the fastest growth, positioning it as the most lucrative By Application segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, United States represented 24.85% of the overall global Psilocybin Assisted Therapy Market size.
- United States is projected to lead the global Psilocybin Assisted Therapy Market size by 2033.
- Across North America, United States is anticipated to hold the dominant position in market size by 2033.
- United States is forecasted to expand at the fastest pace in North America, attaining USD 2223.59 Billion by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 593.85 Billion |
| Market Size In 2033 | USD 2241.42 Billion |
| Largest segment | Depression |
| Units | Revenue in USD Billion |
| CAGR | 15.8% (2025-2033) |
| Segmnetation Covered | |
| By Application |
|
| Formulation |
|
| Therapeutic Setting |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Psilocybin Assisted Therapy Market By Application 2025-2033 (USD Billion)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression | XX.x | XX.x | XX.x | 219.96 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Anxiety | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Post-Traumatic Stress Disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Substance Abuse | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Obsessive-Compulsive Disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Psilocybin Assisted Therapy Market Formulation 2025-2033 (USD Billion)
| Formulation | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquid | XX.x | XX.x | XX.x | 216.76 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Tablet | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capsule | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Powder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injection | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Psilocybin Assisted Therapy Market Therapeutic Setting 2025-2033 (USD Billion)
| Therapeutic Setting | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inpatient | XX.x | XX.x | XX.x | 248.53 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Outpatient | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Residential Treatment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Community-Based Programs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
